The development of a new vaccine as a substitute for Bacillus Calmette–Guerin or to
improve its efficacy is one of the many World Health Organization goals to control …

Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of
improved TB vaccines that boost or replace BCG is a major global health goal. ID93+ GLA …

With over eight million cases of tuberculosis each year there is a pressing need for the
development of new vaccines against Mycobacterium tuberculosis. Subunit vaccines …

Abstract (See the editorial commentary by Dockrell, on pages 1029–31.) Background. There
is currently no safe human challenge model of Mycobacterium tuberculosis infection to …

Mycobacterium tuberculosis is a very successful pathogen that can survive and persist in the
human host in the face of a robust immune response. This immune response is sufficient to …

The increasing incidence of disease associated with HIV infection highlights the crucial role
of the immune response in susceptibility to tuberculosis and has stimulated renewed efforts …

A safe and effective vaccine to prevent tuberculosis is necessary to combat this ancient
disease that kills millions worldwide. Recent advances in our understanding of the host …

Infection by Mycobacterium tuberculosis (Mtb) remains a major global concern and the
available Bacillus Calmette-Guerin (BCG) vaccine is poorly efficacious in adults. Therefore …

Tuberculosis is a leading cause of death from infectious diseases world-wide, and multidrug-
resistant (MDR) tuberculosis continues to spread in many parts of the world. MDR …

Background Previously we have shown that Ag85B-TB10. 4 is a highly efficient vaccine
against tuberculosis when delivered in a Th1 inducing adjuvant based on cationic …